Zydus Lifesciences sets board meeting date to consider buyback of shares. Details here
Zydus Lifesciences board will meet on May 19 to address potential share buyback details. Market participants are now expected to closely track the size, pricing, and structure of the proposed buyback if approved by the board.
Pharma major Zydus Lifesciences will be in focus today after it informed exchanges that its Board of Directors will consider a proposal for buyback of fully paid-up equity shares at its upcoming meeting scheduled for May 19, 2026, along with the company’s financial results.
In a regulatory filing issued on May 13, the pharmaceutical major said the board would evaluate the buyback proposal in accordance with applicable provisions under the Companies Act, SEBI Buy-back Regulations and other relevant laws.
“…the Board of the Company, at its aforesaid meeting, will also consider the proposal for buyback of fully paid-up equity shares of the Company and the matters necessary and incidental thereto, in accordance with the applicable provisions under the Companies Act, 2013, as amended, (including the rules and regulations framed thereunder), the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended, and other applicable laws,” Zydus said in the regulatory filing.
Quick answers to key questions
Zydus Lifesciences' Board of Directors is scheduled to meet on May 19, 2026, to consider a proposal for the buyback of fully paid-up equity shares. This meeting will also cover the company's financial results.
Share buybacks are a common strategy for companies to return surplus cash to shareholders and optimize capital allocation. They can also potentially reduce the number of outstanding shares, which may support shareholder returns in the long term.
Zydus Lifesciences is acquiring Assertio to strengthen its specialty and oncology footprint in the US. Assertio provides a focused commercial platform and an approved oncology asset that aligns with Zydus's strategy.
Zydus Lifesciences plans to utilize Assertio's established US specialty oncology commercial platform and relationships to build and expand its own specialty oncology presence in the United States.
Cipla is building a biosimilars pipeline and aims to add 1-2 products annually over the next five to six years. The company sees a significant long-term opportunity in the fast-growing market for complex biologic drugs.
The company clarified that the proposal would be discussed at the same board meeting that was earlier scheduled to consider the company’s quarterly and annual financial results. Zydus had previously informed exchanges on May 8 regarding the board meeting.
The company also stated that the trading window for directors and designated persons under SEBI’s insider trading regulations will remain closed until May 21, 2026, and will reopen for trading from May 22, 2026. The restriction will also apply in relation to the proposed buyback process.
Share buybacks are often used by companies to return surplus cash to shareholders and optimise capital allocation. They can also reduce the number of outstanding shares in the market, which may support shareholder returns over the longer term.
Investors will now await further details from the May 19 board meeting, particularly regarding the buyback size, record date, entitlement ratio and mode of execution, if the proposal receives approval from the company’s board.
Zydus Life Q3 Results
Zydus Lifesciences posted a 30% year-on-year increase in revenue from operations to ₹6,864.50 crore for the quarter ended December, supported by strong performance across its major business segments, including consumer wellness, North America formulations and international markets.
The Ahmedabad-based drug maker reported a marginal 2% rise in net profit to ₹1,042 crore during the quarter. Profit growth was affected by a one-time adjustment related to gratuity and leave encashment liabilities following the implementation of the government’s new labour code. Excluding the impact of the one-time adjustment, the company’s net profit increased 9% year-on-year to ₹1,110 crore.
The results for the quarter ended March 2026 (Q4FY26) will also be declared on May 19.
Zydus Life Stock Performance
The pharma stock hit its 52-week high of ₹1,059 per share in September 2025 and its 52-week low of ₹835.85 in March 2026. It has been flat but in the red, down 0.5% in the last 1 month; however, it added 26% in the last 3 months. In 1 year, the pharma stock has gained 43%.
Disclaimer: This story is for educational purposes only. Please consult with an investment advisor before making any investment decisions.
About the Author
Pranati Deva is a seasoned financial journalist with over a decade of experience in high-pressure newsroom environments, currently working as a Senior Sub Editor at LiveMint. Over the years, she has developed a reputation for sharp editorial judgement, a strong grasp of market dynamics, and the ability to translate complex financial developments into clear, engaging stories for a wide audience. <br><br> Her core areas of coverage include stock markets, leading listed companies, currencies, and commodities, with a particular strength in fast-paced, real-time market reporting. She is known for handling breaking market news, earnings-driven stock movements, and macroeconomic developments with speed, accuracy, and context—qualities that are essential in financial journalism. <br><br> Pranati has built a diverse and credible professional track record across some of India’s most respected news organisations, including MintGenie, CNBC-TV18, Business Standard and EconomicTimes.com. During her stints at these platforms, she produced data-driven market stories, curated and steered live blogs during volatile trading sessions, and conducted interviews with market veterans, fund managers, economists, and industry experts. Her work often combines on-ground reporting with analytical depth, helping readers make sense of daily market fluctuations and longer-term trends. An alumnus of the Symbiosis Institute of Media and Communications and Hansraj College, University of Delhi, Pranati brings a strong academic foundation to her journalism. She specialises in real-time financial reporting, with a keen focus on precision, balance, and insight, aiming to decode market movements in a way that is both informative and accessible to readers across experience levels.
Catch all the Business News , Market News , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.